Abstract: The present invention relates to a chemically modified heparin, with an antifactor II activity of less than 10 IU/mg, an antifactor Xa activity of less than 10 IU/mg and an average molecular weight (Mw) between about 6.5 and 9.5 kDa. Also disclosed is a method of preparing the heparin and its medical use, including treatment of malaria.

Abstract: The present invention relates to a chemically modified glycosaminoglycan with an antifactor II activity of less than 10 IU/mg, an antifactor Xa activity of less than 10 IU/mg and an average molecular weight (Mw, weight average) from about 4.6 to 6.9 kDa. Also disclosed is a method of preparing the modified glycosaminoglycan and its medical uses.

Abstract: The present invention relates to a method of treating or preventing transthyretin amyloidosis, pharmaceutical composition for use in said treatment or prevention, as well as to a diagnostic method and a kit.

Abstract: The present invention relates to a chemically modified heparin, with an antifactor II activity of less than 10 IU/mg, an antifactor Xa activity of less than 10 IU/mg and an average molecular weight (Mw) between about 6.5 and 9.5 kDa. Also disclosed is a method of preparing the heparin and its medical use, including treatment of malaria.

Abstract: The present invention relates to a chemically modified glycosaminoglycan with an antifactor II activity of less than 10 IU/mg, an antifactor Xa activity of less than 10 IU/mg and an average molecular weight (Mw, weight average) from about 4.6 to 6.9 kDa. Also disclosed is a method of preparing the modified glycosaminoglycan and its medical uses.

Abstract: The invention relates to cells and transgenic non-human mammals having at least one disrupted heparanase allele. The invention further relates to methods of screening therapeutic drug candidates utilizing the heparanase deficient non-human mammals and cells.

Abstract: The invention relates to cells and transgenic non-human mammals having at least one disrupted heparanase allele. The invention further relates to methods of screening therapeutic drug candidates utilizing the heparanase deficient non-human mammals and cells.

Abstract: The invention is directed to a novel purified mouse C5-epimerase, fragments thereof, nucleic acids encoding the same and the recombinant production thereof. The invention is also directed to fragments of such epimerase, especially N-terminal fragments that are useful in fusion protein constructs to enhance the activity of recombinantly-produced heterologous epimerase enzymes.

Abstract: The invention is directed to a novel purified mouse C5-epimerase, fragments thereof, nucleic acids encoding the same and the recombinant production thereof. The invention is also directed to fragments of such epimerase, especially N-terminal fragments that are useful in fusion protein constructs to enhance the activity of recombinantly-produced heterologous epimerase enzymes.

Abstract: The invention is directed to a novel purified mouse C5-epimerase, fragments thereof, nucleic acids encoding the same and the recombinant production thereof. The invention is also directed to fragments of such epimerase, especially N-terminal fragments that are useful in fusion protein constructs to enhance the activity of recombinantly-produced heterologous epimerase enzymes.

Abstract: The invention is directed to a novel purified mouse C5-epimerase, fragments thereof, nucleic acids encoding the same and the recombinant production thereof. The invention is also directed to fragments of such epimerase, especially N-terminal fragments that are useful in fusion protein constructs to enhance the activity of recombinantly-produced heterologous epimerase enzymes.

Abstract: An isolated or recombinant DNA sequence coding for a mammalian, including human, glucuronyl C5-epimarase or a functional derivative thereof capable of converting D-glucuronic acid (GlcA) to L-iduronic acid (IdoA); a recombinant expression vector comprising such DNA sequence; a host cell transformed with such recombinant expression vector; a process for the manufacture of a glucuronyl C5-epimerase or functional derivative thereof capable of converting GlcA to IdoA, comprising cultivation of a cell-line transformed with such recombinant expression vector; and a glucuronyl C5-epimerase or functional derivative thereof prepared by such process.

Abstract: An isolated or recombinant DNA sequence coding for a mammalian, including human, glucuronyl C5-epimerase or a functional derivative thereof capable or converting D-glucuronyl acid (GlcA) to L-iduronic acid (IdoA); a recombinant expression vector comprising such DNA sequence; a host cell transformed with such recombinant expression vector; a process for manufacture of a glucuronyl C5-epimerase or functional derivative thereof capable of coverting GlcA to IdoA, comprising cultivation of a cell-line transformed with such recombinant expression vector; and a glucuronyl C5-epimerase or functional derivative thereof prepared by such process.

Abstract: The invention is directed to a novel purified mouse C5-epimerase, fragments thereof, nucleic acids encoding the same and the recombinant production thereof. The invention is also directed to fragments of such epimerase, especially N-terminal fragments that are useful in fusion protein constructs to enhance the activity of recombinantly-produced heterologous epimerase enzymes.